Chemotherapy News and Research

Latest Chemotherapy News and Research

Article describes immune-related adverse events with newly approved melanoma drug

An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. K-hler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.

23 Aug 2012

Chemotherapy during pregnancy: an interview with Professor Sibylle Loibl

The incidence is about 1-3% of all breast cancers. The incidence seems to be increasing due to women delaying their childbearing to when they are in their thirties.

22 Aug 2012

Radiation therapy alone no longer the best choice for early follicular lymphoma

A University of Rochester Medical Center study published in the Journal of Clinical Oncology, challenges treatment guidelines for early stage follicular lymphoma, concluding that six different therapies can bring a remission, particularly if the patient is carefully examined and staged at diagnosis.

22 Aug 2012

VolitionRX to initiate NuQ blood-based tests in colorectal cancer clinical trial

VolitionRX Limited, a life sciences company focused on developing blood-based diagnostic tests, announces that its subsidiary Belgian Volition has signed an agreement with the Biobank of CHU UCL Mont-Godinne, an academic hospital in Yvoir, Belgium.

22 Aug 2012

Bile duct cancer chosen as next indication for PCI Biotech

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has chosen bileduct cancer as the next indication for the use of its PCI (photochemical internalisation) localised cancer therapy. In this indication PCI Biotech’s proprietary photosensitiser Amphinex® will be used in combination with the generic cytotoxic agent gemcitabine. The aim is to start the clinical Proof of Concept study within end of 1H 2013.

21 Aug 2012

Mayo Clinic receives approval for construction of new building on Phoenix campus

Mayo Clinic has been granted approval for construction of a 217,200 square-foot building on its Phoenix campus, a major expansion that will create a single-site, integrated Cancer Center. Mayo Clinic Cancer Center is the only National Cancer Institute-designated comprehensive cancer center with a multi-site, national presence, which allows us to serve a broad and diverse group of patients.

21 Aug 2012

National approach can help manage drug shortages in Canada

Canada needs a national approach to managing its supply of pharmaceutical drugs, starting with a mandatory reporting system for drug shortages, argues an editorial in CMAJ (Canadian Medical Association Journal) and CPJ (Canadian Pharmacists Journal).

21 Aug 2012

Thiabendazole drug slows tumor growth and shows promise as chemotherapy for cancer

An inexpensive antifungal drug, thiabendazole, slows tumor growth and shows promise as a chemotherapy for cancer. Scientists in the College of Natural Sciences at The University of Texas at Austin made this discovery by exploiting the evolutionary relatedness of yeast, frogs, mice and humans.

21 Aug 2012

Enzalutamide extends castration-resistant prostate cancer survival

Enzalutamide treatment significantly improves survival in men with castration-resistant prostate cancer, demonstrate phase III trial results published in TheNew England Journal of Medicine.

20 Aug 2012

HPV genotype may alter chemoradiotherapy outcome

Human papillomavirus genotype predicts whether patients with cervical cancer will benefit from concurrent chemoradiation therapy, study findings suggest.

20 Aug 2012

Lack of certain gene occurs in almost 28% of breast cancers

More than one out of every four cases of breast cancer is associated with a specific, missing gene - a finding that could have significant implications for chemotherapy treatments, according a recent study by Cornell University researchers.

20 Aug 2012

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

ARIAD Pharmaceuticals, Inc. today announced the initiation of a multi-center Phase 1/2 clinical trial in Japan of ponatinib, the Company's investigational BCR-ABL inhibitor.

20 Aug 2012

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Cancer may be the Harry Houdini of diseases—it often finds devious ways to escape treatment. Because cancer disables our cellular quality control mechanisms, rampant mutations that cause tumor cells to grow uncontrollably can also generate resistance to anticancer drugs. Even if 99 percent of the tumor is destroyed, that 1 percent can come roaring back. How do we knock out that 1 percent? By attacking the cancer from multiple angles, using multiple treatments and strategies.

20 Aug 2012

Computer simulations shed light on dynamic structure of major target for anti-cancer drugs

Using advanced computer simulations, University of Utah College of Pharmacy researchers have produced moving images of a protein complex that is an important target for anti-cancer drugs.

18 Aug 2012

Two eminent cancer specialists and EORTC to be recognized at ESMO 2012 Congress

The European Society for Medical Oncology (ESMO) announced today the names of two eminent cancer specialists and one European institution that will be recognized for their contribution to the advancement of medical oncology at the ESMO 2012 Congress.

17 Aug 2012

Study examines whether eribulin offers added benefit to women with breast cancer

Eribulin was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.

17 Aug 2012

Peptide combinations might offer more effective cancer therapy

Two studies suggest that two peptide agents used either together or individually with a low-dose of a standard chemotherapy drug might offer more effective cancer therapy than current standard single-drug treatments.

17 Aug 2012

Enzalutamide drug extends survival in people with advanced prostate cancer

Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.

17 Aug 2012

Pregnant women who undergo chemotherapy do not appear to increase their baby’s risk of complications

The babies of breast cancer patients who undergo chemotherapy while pregnant do not appear to be at higher risk of complications, according to an Article published Online First in The Lancet Oncology.

16 Aug 2012

Researchers discover mechanisms responsible for chemoresistance in ovarian cancer

The presence of multiple ovarian cancer genomes in an individual patient and the absence or downregulation of the gene LRP1B are associated with the development of chemoresistance in women with the high-grade serous cancer subtype of ovarian cancer whose disease recurs after primary treatment. These study results are published in Cancer Research, a journal of the American Association for Cancer Research.

16 Aug 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

Article describes immune-related adverse events with newly approved melanoma drug

Chemotherapy during pregnancy: an interview with Professor Sibylle Loibl

Radiation therapy alone no longer the best choice for early follicular lymphoma

VolitionRX to initiate NuQ blood-based tests in colorectal cancer clinical trial

Bile duct cancer chosen as next indication for PCI Biotech

Mayo Clinic receives approval for construction of new building on Phoenix campus

National approach can help manage drug shortages in Canada

Thiabendazole drug slows tumor growth and shows promise as chemotherapy for cancer

Enzalutamide extends castration-resistant prostate cancer survival

HPV genotype may alter chemoradiotherapy outcome

Lack of certain gene occurs in almost 28% of breast cancers

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Computer simulations shed light on dynamic structure of major target for anti-cancer drugs

Two eminent cancer specialists and EORTC to be recognized at ESMO 2012 Congress

Study examines whether eribulin offers added benefit to women with breast cancer

Peptide combinations might offer more effective cancer therapy

Enzalutamide drug extends survival in people with advanced prostate cancer

Pregnant women who undergo chemotherapy do not appear to increase their baby’s risk of complications

Researchers discover mechanisms responsible for chemoresistance in ovarian cancer

Cancer Research - Second Edition eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in